MGC Pharmaceuticals Limited Appointment of Non-Executive Director (3212B)

TIDMMXC

RNS Number : 3212B

MGC Pharmaceuticals Limited

01 June 2023

1 June 2023

ASX Code: MXC

LSE Code: MXC

Appointment of Non-Executive Director

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, is pleased to announce the appointment of Mr. Layton Mills as a Non-Executive Director of the Company effective immediately.

Mr. Mills is an experienced life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing significant experience across human and animal health in pharmaceutical and consumer healthcare.

Mr. Mills is the founder of CannPal Animal Therapeutics Pty Ltd, an Animal Health Company developing cannabinoid-based veterinary medicines for FDA-CVM registration, which he led through an Initial Public Offering on the Australian Stock Exchange, followed by an acquisition by AusCann Group Holdings in 2021 where he served as CEO. Mr Mills is also the founder and Managing Director of Subgenix Lifesciences, an early-stage biotechnology Company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs .

He has extensive international business experience having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.

-Ends-

Authorised for release by the board of directors, for further information please contact:

 
 MGC Pharmaceuticals Ltd                        MGC Pharmaceuticals Ltd 
  Roby Zomer                                     Arron Canicais / Rowan Harland 
  CEO & Managing Director                        Joint Company Secretaries 
  [phone]                                [phone] 
  [e-mail]                           [e-mail] 
 UK Brokers                                     UK Brokers 
  Peterhouse Capital                             Oberon Capital 
  Charles Goodfellow / Lucy Williams             Aimee McCusker / Adam Pollock 
  / Duncan Vasey                                 [phone] 
  [phone]                               [e-mail] 
  [e-mail] / [e-mail]    [e-mail] 
 UK IR/PR Advisers 
  IFC Advisory 
  Graham Herring / Tim Metcalfe / 
  Zach Cohen 
  [phone] 
  [e-mail] 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZZGGVVMGGFZG

(END) Dow Jones Newswires

June 01, 2023 02:30 ET (06:30 GMT)